REG - C4X Discovery - Notice of Results

C4X Discovery HoldingsAnnouncement

09/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211209:nRSI0372Va&default-theme=true

RNS Number : 0372V  C4X Discovery Holdings PLC  09 December 2021

 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

 

Notice of Results

 

9 December 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, will be announcing its full year results for the year
ended 31 July 2021 on Monday 13 December 2021.

 

- ENDS -

For further information, please contact:

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Chris Gardner, Matthew Neal                               +44 (0)203 709 5700

 

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world‑leading medicines, which are developed by our
partners for the benefit of patients.  We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, neurodegeneration, oncology and addictive disorders.  Our
commercially attractive portfolio ranges from early stage novel target
opportunities to late stage Drug Discovery programmes ready for out-licensing
to partners and we have two commercially partnered programmes with one
candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development.  Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio. For more information
visit us at www.c4xdiscovery.com (http://www.c4xdiscovery.com) or follow us on
twitter @C4XDiscovery.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORUWRBRAWUURAA